AURORA, Ontario, Oct. 28 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the year ended July 31, 2008.
During the 2008 fiscal year, the Company continued to make progress with its development initiatives for its lead drug candidates, L-DOS47 and Topical Interferon Alpha-2b. The following are selected highlights during the 2008 fiscal year and subsequent to year-end.
-- Signed an agreement with a fill/finish provider to perform vial
packaging of L-DOS47 for clinical testing.
-- Signed an agreement with a company specializing in lyophilization
(freeze-drying) to develop the L-DOS47 vial packaging format
-- Signed a second, more definitive agreement with our L-DOS47 active
drug substance and bulk drug product manufacturer to further scale
up the GMP production process in preparation for clinical testing.
-- Awarded a second U.S. patent protecting the use of targeted
DOS47-based therapeutics, such as L-DOS47, in combination
therapeutic regimens with certain chemotherapeutic agents
-- Topical Interferon Alpha-2b
-- Received regulatory approval to open sites in Germany for the
ongoing Phase II clinical trial in patients with ano-genital warts.
-- Conducted meetings with German regulators as a preliminary step
towards filing a CTA for a planned, large, randomized,
placebo-controlled, double-blind Phase III European clinical trial
in patients with low-grade cervical lesions.
-- Signed an agreement to further scale up the production of Topical
Interferon Alpha-2b in anticipation of conducting the planned
European Phase III clinical trial in patients with low-grade
cervical lesions, as well as
|SOURCE Helix BioPharma Corp.|
Copyright©2008 PR Newswire.
All rights reserved